# Journey Medical Corporation (DERM)

> Source: Nexqual · https://nexqual.com/DERM · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Journey Medical Corporation (DERM), nexqual.com/DERM" · informational, not investment advice.

**Price:** USD 5.13 (-2.94% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 5.28 · day 5.09–5.34 · 52w 4.31–9.56 · market cap $145M · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (4 analysts), mean target USD 13.75 (range 13–15).
- Total return with dividends: 1Y -30.7% vs S&P 500 +18.1%; 5Y -48.2% vs S&P 500 +85.1%.
- Next earnings: 2026-11-11, EPS estimate USD 0, revenue estimate $21.4M.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 4 analysts; mean target USD 13.75 (low 13, high 15).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-13 | B. Riley Securities | Target raised | Buy | $12 → $15 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-11-08) |
|---|---|---|
| Total return | -30.7% | -48.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -30.8% | -12.5% |
| Volatility (annualized) | 69.0% | 83.7% |
| Max drawdown | -52.6% (Jan 2026→Mar 2026) | -89.3% (Nov 2021→May 2023) |

## Peers (Drug Manufacturers - Specialty & Generic)
BHC (Bausch Health Companies Inc.) USD 6.31 +7.13% · HCM (HUTCHMED (China) Limited) USD 13.94 +3.26% · LQDA (Liquidia Corporation) USD 34.78 +29.73% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.65 +2.98% · INDV (Indivior Pharmaceuticals, Inc.) USD 33.62 -5.08% · RGC (Regencell Bioscience Holdings L) USD 9.52 +16.24%

## More
Full page: https://nexqual.com/DERM · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt